Xianju Pharmaceutical gains approval for estradiol tablets, expands product line

Zhejiang Xianju Pharmaceutical announced on September 20, 2025, that it has received a domestic drug registration certificate from the National Medical Products Administration for its estradiol tablets. This approval pertains to 1mg estradiol tablets, a chemical drug. The company highlighted that this approval enriches its product pipeline and strengthens its market competitiveness.

The estradiol tablets, 1mg, are comparable to the reference preparation ESTRADIOL, developed by Barr Laboratories Inc. The approved indications for Xianju Pharmaceutical's estradiol tablets include the treatment of estrogen deficiency-related diseases and the prevention of osteoporosis.

The company further cautioned investors about the inherent uncertainties in pharmaceutical R&D, production, and sales, which are susceptible to national policies and market conditions. This announcement follows the company's second extraordinary general meeting of 2025, held on September 19, 2025.